
Achaogen develops drugs to treat infectious disease and address the problem of drug resistance.

Congratulations to OPTM on FDA approval for Dificid! We need more new antibiotics.
8:49pm May 29th from AchaogenGreat article on companies addressing C. diff and MRSA–The pipeline is stocked for MRSA but empty for Gram-negatives. http://bloom.bg/keNHtx
1:54pm May 17th from AchaogenWe’ll be tweeting thoughts about our company, antibiotic R&D, bacterial resistance, and more. Spread the word and send us your feedback!
1:53pm May 17th from AchaogenHello world from Achaogen –
1:52pm May 17th from Achaogen